Login to Your Account



Other News To Note


Monday, September 30, 2013

• Anida Pharma Inc., of Cambridge, Mass., said it was awarded funding from the Michael J. Fox Foundation for Parkinson’s Research to conduct preclinical research using its lead compound for neurodegenerative diseases, Neuroprotectin D1, an endogenous DHA-derived lipid mediator that regulates circuits of resolution.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription